- NCBI Gene Id:
- Protein Name:
- Tumor necrosis factor receptor superfamily member 5
- Alias Symbols:
- p50, Bp50, CDW40, MGC9013, TNFRSF5, CD40
- Replacement Item:
- This antibody may replace item sc-112948 from Santa Cruz Biotechnology.
- Description of Target:
- MOUSE ANTI HUMAN CD40:Low Endotoxin
- Protein Size (# AA):
- IHC-AFF, FC, IP, IHC-FFPE
- Tissue Tool:
- Find tissues and cell lines supported by DNA array analysis to express CD40.
- RNA Seq:
- Find tissues and cell lines supported by RNA-seq analysis to express CD40.
- Predicted Species Reactivity:
- Predicted Homology Based on Immunogen Sequence:
- Product Format:
- Purified IgG - liquid
- Reconstitution and Storage:
- Store at -20oC only.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- Printable datasheet for anti-CD40 antibody - OASA01976
- Low Endotoxin
- Application Info:
- Flow Cytometry: 1/100 - 1/200
(1) Special conditions apply - Please see [*]
- Application Data:
- Application #1: Staining of human peripheral blood lymphocytes with Mouse anti Human CD40: Alexa Fluor 488
Application #2: Staining of human peripheral blood lymphocytes with Mouse anti Human CD40:Alexa Fluor 647
Application #3: Staining of human peripheral blood lymphocytes with Mouse anti Human CD40:Biotin
Application #4: Staining of human peripheral blood lymphocytes with Mouse anti Human CD40:FITC
Application #5: Staining of human peripheral blood lymphocytes with Mouse anti Human CD40:RPE
- Additional Information:
- Fusion Partners: Spleen cells from immunised BALB/c mice were fused with cells of the mouse NS1 myeloma cell line.
Histology Positive Control Tissue: Human Tonsil
- Preparation: Purified IgG prepared by affinity chromatography on Protein A
Preservative Stabilisers: None present
- Approx Protein Conc: IgG concentration 1.0 mg/ml
Buffer Solutions: Tris buffered saline
Endotoxin Level: < 0.01EU/ug
- Target Reference:
- 1. Quadbeck, B. et al. (2002) Maturation of thyroidal dendritic cells in Graves Disease. Scand. J. Immunol. 55: 612-620.
2. Kirsch, B. M. et al . (2005) The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. Arthritis Res. Ther. 7: R694-R703.
3. Cheadle, E. et al. (2003) Mycobacterium bovis bacillus Calmette-Guerin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism. Immunology.108: 79-88.
4. Carpenter, E.L. et al. (2009) Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med. 7: 93.
5. Garcia-Nieto, S. et al. (2010) Laminin and Fibronectin Treatment Leads to Generation of Dendritic Cells with Superior Endocytic Capacity. PLoS ONE. 5: 1-10.
6. Wang, Y.S. et al. (2007) Characterization of canine monocyte-derived dendritic cells with phenotypic and